ArticlePediatric research2026
Prognostic value of cystatin C for chronic kidney disease in pediatric urologic malformations.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the prognostic value of serum cystatin C for predicting 10-year major adverse kidney events (MAKE) in pediatric patients with urologic malformations (UTMs).
methodsThis retrospective cohort study used the TriNetX global federated research network of electronic health records. Children aged 0-18 years with UTMs (including congenital urinary tract anomalies, vesicoureteral reflux, obstructive uropathy, neurogenic bladder, and spina bifida) and available serum cystatin C measurements were included. The primary outcome was MAKE, defined as the first occurrence of dialysis initiation, kidney transplantation, chronic kidney disease, albuminuria, or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² within 10 years. Secondary outcomes were the individual components of MAKE.
resultsAfter 1:1 propensity score matching, 2062 patients were analyzed (mean follow-up 1025 days). Elevated cystatin C (≥1.3 mg/L) was associated with higher MAKE incidence (39.3% vs 29.2%; HR 2.5, 95% CI 2.00-3.12, p < 0.001). Significant risks were observed for CKD (HR 3.55), dialysis (HR 9.09), and albuminuria (HR 1.83). No significant differences were found for renal transplantation (HR 0.52) or eGFR decline <60 (HR 1.48).
conclusionsHigh cystatin C independently predicts MAKE and CKD in children with UTMs. Routine testing may enable early risk stratification and guide long-term renal surveillance. IMPACT: Pediatric patients with urologic malformations have increased chronic kidney disease risk, often requiring dialysis with a significant healthcare and quality-of-life burden. Traditional markers like serum creatinine and eGFR have limitations in detecting early renal impairment in growing children. Serum cystatin C, unaffected by muscle mass or growth, offers superior kidney function assessment but has not been evaluated for predicting long-term outcomes in pediatric urinary tract malformations. This study is the first to evaluate cystatin C's prognostic value for Major Adverse Kidney Events in this population. Incorporating cystatin C into routine monitoring may improve early risk stratification and guide surveillance strategies.
Identifiers
41513978What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.